# IMbrave150

Source: https://onco.cc/trials/imbrave150/  
OnCo record `imbrave150` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The trial that ended the sorafenib era: immunotherapy plus an anti-VEGF antibody became the new first-line standard for liver cancer.

## Summary

IMbrave150, trial NCT03434379 sponsored by Roche and reported in 2020, ended the sorafenib era by making atezolizumab plus bevacizumab the new first-line standard for unresectable hepatocellular carcinoma. It randomised 501 patients and met both primary endpoints of overall and progression-free survival, with a much higher response rate, becoming the first regimen to beat sorafenib on survival, though bevacizumab's bleeding risk means patients need endoscopy for varices first. OnCo links it to PD-L1 and VEGF as targets, atezolizumab, Richard S. Finn, Ann-Lii Cheng and Ho Yeong Lim, and to the caution pairing about bevacizumab with untreated varices; the result is consistent with the class effect seen in CARES-310 and ORIENT-32. Whether it remains the preferred first-line regimen against dual checkpoint blockade from HIMALAYA and CheckMate 9DW is the open question.

## Fields

- Kind: Trial
- Status: positive
- Last checked: 2026-09-07
- Registry id: NCT03434379
- Phase: 3
- Setting: First-line unresectable HCC: atezolizumab + bevacizumab vs sorafenib
- Sponsor: Roche
- Enrolled: 501
- Result: OS 19.2 vs 13.4 months, HR 0.66.
- Outcomes: Overall survival (updated): Atezolizumab + bevacizumab 19.2 months vs Sorafenib 13.4 months, HR 0.66; Progression-free survival: Atezolizumab + bevacizumab 6.9 months vs Sorafenib 4.3 months, HR 0.65; Objective response rate: Atezolizumab + bevacizumab 30% vs Sorafenib 11%
- Replication: Consistent with real-world cohorts and with the anti-VEGF + PD-(L)1 class effect seen in CARES-310 and ORIENT-32.

## Sources

- ClinicalTrials.gov NCT03434379: https://clinicaltrials.gov/study/NCT03434379
- IMbrave150 response characterisation: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366100/

## Connected records

- cancers: [Advanced hepatocellular carcinoma (BCLC C)](https://onco.cc/cancers/hcc-advanced/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Intermediate hepatocellular carcinoma (BCLC B)](https://onco.cc/cancers/hcc-intermediate/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- targets: [PD-L1](https://onco.cc/targets/pdl1/), [VEGF / VEGFR](https://onco.cc/targets/vegf/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/)
- companies: [Roche / Genentech](https://onco.cc/companies/roche-genentech/)
- people: [Ann-Lii Cheng](https://onco.cc/people/ann-lii-cheng/), [Ho Yeong Lim](https://onco.cc/people/lim-ho-yeong/), [Richard S. Finn](https://onco.cc/people/richard-finn/)
- pairings: [Caution: bevacizumab-based regimens with untreated varices](https://onco.cc/pairings/io-varices-caution/)
- ideas: [Immunotherapy downstaging to transplant with a safe washout](https://onco.cc/ideas/idea-hcc-io-before-transplant/)
- key papers: [Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma](https://onco.cc/key-papers/paper-atezolizumab-hcc-j-hepatol-2022/)

---
JSON: https://onco.cc/api/v1/entities/imbrave150.json